This product is no longer promoted on Made-in-China.com. If you find any infringement or sensitive information of it, please contact us for handling. Thank you.
  • Westren Medicine Coumadin Tablets for Human Pharma
  • Westren Medicine Coumadin Tablets for Human Pharma
  • Westren Medicine Coumadin Tablets for Human Pharma

Westren Medicine Coumadin Tablets for Human Pharma

Diamond Member Since 2020

Suppliers with verified business licenses

Trading Company

Basic Info.

Model NO.
tablets
Pharmaceutical Technology
Natural Product Extraction
Dosage
1mg
Use
Oral
Transport Package
Box
Specification
1mg
Origin
China
Production Capacity
500000box/Month

Product Description

ABout US
WE CAN PROVIDE MAKE FORMEULATION (OEM)
 
 
Adding my whatsapp will have good price with you .
Service we can provide:
1. Mixed container, we can mix different items in one container.
2. Quality control, before shipment, free sample for test. After shipment, keep sample for 3 years
3. Prompt shipment with professional documents
4. Packing as your request, with photo before shipment.
DMS CHEMICAL PHARMACEUTICAL INC.LTD
http://dmsdrugs.en.made-in-china.com/
Product Name Coumadin Tablets
Contians Coumadin 1mg
Package 120tablet/box OR 1000tablets/bottle
Store Store COUMADIN at 59°F to 86°F (15°C to 30°C).
Keep COUMADIN in a tightly closed container
Keep COUMADIN out of the light and moisture.
Follow your healthcare provider or pharmacist instructions about the right way to throw away outdated or unused COUMADIN.
Females who are pregnant should not handle crushed or broken COUMADIN tablets.
Application What is COUMADIN?
COUMADIN is prescription medicine used to treat blood clots and to lower the chance of blood clots forming in your body. Blood clots can cause a stroke, heart attack, or other serious conditions if they form in the legs or lungs.
  COUMADIN is indicated for:

Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).

Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.

Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now